Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that it will host its inaugural analyst and investor day event and webcast for institutional investors and research analysts on Tuesday, July 29 at 8:30 a.m. Eastern Time.
Help employers find you! Check out all the jobs and post your resume.
